> **Layer 1** · Medicine & Health Sciences · `H11-IMMUNOTHERAPIA`

## Purpose
The H11-IMMUNOTHERAPIA agent focuses on the design, modulation, and personalized deployment of biologics and immunotherapies, including CAR-T cell therapies, monoclonal antibodies, and immune checkpoint inhibitors. It models immune system dynamics to maximize tumor/pathogen eradication while minimizing autoimmune-like adverse events (e.g., cytokine release syndrome).

## Technical Deep-Dive
H11-IMMUNOTHERAPIA uses ordinary differential equations (ODEs) to model predator-prey dynamics between T-cells and tumor cells within the tumor microenvironment (TME). It integrates spatio-temporal modeling of cytokine diffusion and immune cell infiltration using reaction-diffusion equations.

To predict checkpoint inhibitor efficacy (e.g., PD-1/PD-L1 axis), the agent employs graph neural networks (GNNs) over multiplex immunohistochemistry imagery, evaluating the spatial proximity of CD8+ T-cells to regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs).

## Architecture

### Input Contract
| Field | Type | Description |
|-------|------|-------------|
| tumor_biomarkers | TumorProfile | HLA types, neoantigen burden |
| immune_repertoire | TCRProfile | T-cell receptor sequencing data |
| tme_spatial_graph | SpatialGraph | Cell-cell interactions from mIHC |

### Output Contract
| Field | Type | Description |
|-------|------|-------------|
| therapy_design | BiologicDesign | Recommended antibody/CAR construct |
| crs_risk_index | float | Probability of cytokine release syndrome |
| response_trajectory| TimeSeries | Predicted tumor volume over time |

### State Schema
Maintains a dynamic equilibrium model of patient-specific immune homeostasis, represented as a continuous state-space model.

## Dependencies
### Upstream
- H11-ONCOLOGIA: Provides tumor mutational burden and neoantigen data.
- H11-IMMUNOLOGIA: Provides baseline immune system state and HLA typing.
### Downstream
- H11-PRECISIONMED: Uses therapy design for final treatment planning.

## Failure Modes
- Immune Evasion: Tumor downregulation of MHC-I rendering CAR-T/TCR therapy ineffective.
- Off-Target Toxicity: Cross-reactivity of engineered T-cells with healthy tissues sharing similar epitopes.
- Exhaustion Modeling Failure: Underestimating the rate at which T-cells enter an exhausted (TIM-3/LAG-3 positive) state.

## Performance Characteristics
- Compute: Extremely high for solving PDE-based spatial diffusion models. GPU acceleration required.
- Memory: Large memory footprint for storing spatial graphs of the TME (up to 32GB per sample).

## Research References
- Mathematical modeling of CAR T-cell therapy dynamics.
- Spatial organization of the tumor microenvironment and immunotherapy response.

## Implementation Notes
Leverages JAX for differentiable ODE solvers and DGL (Deep Graph Library) for the TME spatial GNNs.
